Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Shawking. Pete Patterson sounds very knowledgeable. Very promising for Lexaria to get a foot in the door in the European market in it's infancy. Good interview on the video. Funny about the Kelowna connection too.
Pete Patterson started Vitalis in Kelowna, BC and Valcon gets their extraction equipment from Vitalis.
https://www.kelownadailycourier.ca/business_news/article_f5ce6d80-5e05-11e8-aa5b-2f674361596d.html
Pete Patterson CEO of Valcon interview
GMP Certified means hardly a garage based company!
Valcon Medical is a European contract manufacturing organization ("CMO"), specialized in the manufacturing of medical cannabis extracts for the European Union ("EU") and the UK. Valcon is GMP certified and licensed under the Danish medical cannabis program to manufacture cannabis products that require physician-patient consultation.
Is Valcon a real company generating any revenue or is this a shell deal by Bunka??
I see they raised 12.6 mil a few years ago, but is this just a dispensary or an out of the garage company?
Lexaria Grants License to Valcon Medical for the European Market
Contract Manufacturing Organization first in Europe to License DehydraTECH
Lexaria will receive milestone fees and royalty payments from product sales
Kelowna, British Columbia - June 2, 2022 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce the awarding of a European and United Kingdom (“UK”) DehydraTECH license for medical cannabis applications from Lexaria Pharmaceutical Corp. to Valcon Medical A/S (“Valcon”).
Valcon Medical is a European contract manufacturing organization (“CMO”), specialized in the manufacturing of medical cannabis extracts for the European Union (“EU”) and the UK. Valcon is GMP certified and licensed under the Danish medical cannabis program to manufacture cannabis products that require physician-patient consultation.
Valcon products will span non-registered medical products through magistral programs, country-level market-authorized medical cannabis products through pilot programs, and country and/or EU Commission registered medical cannabis products. These products include bulk powders or solid oral dosage forms including, but not limited to, powder-filled capsules, compressed tablets, pills, oral melts, and topical creams and lotions with or without patch integration.
The non-exclusive license includes a combination of defined milestone fees payable to Lexaria upon completion of batch validation and marketing authorization application approvals for the first DehydraTECH-enabled products completed by Valcon for each of several product categories it shall pursue, together with defined royalties payable to Lexaria on revenues generated from Valcon’s product sales.
“We are very excited to have licensed Lexaria’s DehydraTECH technology for what we expect will be rapid growth across the European markets,” said Pete Patterson, CEO of Valcon Medical A/S. “As Valcon continues to build out its manufacturing capabilities we are developing new IP and partnering with industry leaders. Lexaria has developed and patented an incredible technology which will benefit medical cannabis patients with enhanced bioavailability with a quicker effect onset. Backed by substantial clinical efficacy studies, Valcon will bridge the extensive work that Lexaria has done in the US, over to Europe.”
Lexaria notes the potential for growth in utilization of DehydraTECH across these European markets given the advanced technical capabilities of Valcon, and their business focus on providing CMO services to a wide spectrum of companies active in the EU.
About Valcon Medical A/S
Founded in 2018, Valcon Medical is the most advanced medical cannabis manufacturer in its field in Europe and leads the cannabis industry in manufacturing capacity and production of the highest quality full spectrum extracts and API cannabinoid isolates. Valcon Medical is supported by a shareholder group comprised of some of the leading cannabis investment funds in the world, including Altitude Capital, Artemis Growth Partners, Enexis AB, Greenfield Global Opportunities, and Nimb Capital.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
News Out - European Medical Deal https://ir.lexariabioscience.com/news-events/press-releases/detail/177/lexaria-grants-license-to-valcon-medical-for-the-european
Nice, but more and more of the same. Good stuff, works well.............stock is at $2.20. Are those the true facts
Ted Ohashi May 30
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_3230d4f73e0948dc8f8ec92572714bad.pdf
Here are some thoughts on Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW). Blood pressure is equal to cardiac output times systemic vascular resistance. In other words, the pressure the
blood is exerting on the walls of your artery is equivalent to cardiac output (the amount of blood being
pushed out of your left ventricle over time) multiplied by the systemic vascular resistance or the resistance your arterials are putting on the blood behind it. This is important because your arterials have
smooth muscle wrapped around them and the smooth muscle can either constrict or dilate. If the
smooth muscle constricts, it makes is harder for the blood to pass through, or, it increases blood pressure. On the other hand, if it dilates, there is more room for the blood to pass through and the blood
pressure declines. This means that all the antihypertensive drugs we use to treat blood pressure either
reduces the cardiac output or it reduces systemic vascular resistance.
Lexaria’s human clinical study HYPER-H21-2 confirmed DehydraTECH™-processed cannabidiol
(CBD) reduced arterial stiffness. This finding potentially broadened its application to the treatment of
cardiovascular and other disease states beyond hypertension. DehydraTECH™ has already shown
tremendous promise in lowering blood pressure but if it can actually contribute to the treatment of the
causes of high blood pressure or other diseases, that would be a significantly more important, valuableadded. President John Docherty called it a “major discovery.” He went on to say, "We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people
worldwide, and we are optimistic that our latest findings could have future widespread implications for
promotion of improved human health and wellness."
“The efficacy of blood pressure treatment and differences in efficacy between different types of antihypertensive agents is strongly correlated with measuring arterial stiffness…DehydraTECH-CBD from
study HYPER-H21-2 appear to have been at least partially due to improvements in arterial stiffness.”
“To have decreased arterial stiffness to the degree demonstrated in our present study after only a
single day of dosing with DehydraTECH-CBD is quite remarkable and will be more thoroughly investigated in Lexaria's upcoming 6-week hypertension study HYPER-H21-4, where multiple doses over this
period are expected to demonstrate additional benefits against hypertension and arterial stiffness.”
9
An article by Rekha Mankad, M.D. of the Mayo Clinic confirms this information in a slightly different
way. Blood pressure readings are in two numbers. The top number is the systolic pressure or the
highest pressure the heart exerts while beating and the second number is the diastolic pressure or the
pressure in the arteries between heart beats. The systolic pressure (say 120) minus the diastolic pressure (say 80) is the pulse pressure (120-80=) 40. Generally, a pulse pressure over 40 is considered
unhealthy. A pulse pressure of over 60 is considered a risk factor for cardiovascular disease. Stiffness
of the aorta is the leading cause of higher blood pressure and is thought to contribute to stiffening of
the arteries. Treating high blood pressure usually means reducing pulse pressure.
What does this tell us? It means the ability of DehydraTECH-CBD as first detected in HYPER-H21-2
to lower blood pressure was due, in part, to improvements in arterial stiffness. This will be one important
finding to look for when we see the results from hypertension study HYPER-H21-4 that is currently
underway. If there are additional signs of reductions in arterial stiffness the market response could be
explosive. We could see preliminary results from HYPER-H21-4 as early as late July and certainly
almost complete results by early fall.
The hypertension market is valued at $28 billion per year and is expected to continue growing as one
of the world's top health problems. Geographically, some of the highest rates of growth are expected
in more recently industrialized nations such as China and India. Over 1.1 billion people worldwide suffer from hypertension - elevated blood pressure. Hypertension is a major risk factor for cardiovascular
and cerebrovascular disease, and accounts for approximately 45% of cardiovascular disease mortality
and morbidity worldwide. Drugs focused on blood pressure and related conditions such as Lipitor and
Plavix are some of the highest selling drugs in the world. There are several hypertension drugs that
each generate $1 billion per year or more in revenue.
Finally, in my latest interview with CEO Chris Bunka, we discussed the growing potential for a significant commercial agreement. The company has been in discussions with more high profile businesses
than ever before in LEXX’s history. If one of these results in a commercial contract, it could also help
get the stock price moving up towards a valuation that some multiple of the current price that I believe
is more realistic.
Conclusion: Although the cannabis stocks are trading in a volatile and uncertain fashion, the type of
news that LEXX is capable of generating over the next few months can move the stock higher against
the general trend.
Along with many
stocks, LEXX is
trading at an excessively low
level. The current
market cap
10
according to Yahoo Finance is $12.3 million. For a company with multiple prospects that offer the potential for a breakthrough market re-evaluation, I consider this an excessive undervaluation and an
opportunity waiting to happen
Cannadips Co-Founder Case Mandel recently posted that Cannadips has solved "The Sleep Problem" and that we should be looking out for a new product soon! Hopefully and probably likely to be using DehydraTECH. https://www.linkedin.com/feed/update/urn:li:activity:6935714152082522113/
Perhaps a reminder that IP can be bought from someone else if patents are already owned. LEXX started the company by puchasing the Vipova Tea Patents. https://www.lexariabioscience.com/news/lexaria-bioscience-acquires-100-ownership-poviva-tea-llc/
Perhaps Chris has his eye on some useful IP.
https://www.google.com/amp/s/www.networknewswire.com/lexaria-bioscience-corp-nasdaq-lexx-leveraging-growing-commercial-opportunities/amp/
What's with this remark outta nowhere...?
TAX LOSS - imho - I messed up on this one - still holding . glta
Has Albert Jr just become a director? He has less shares than me, but he is in the green.
They should give back some of their compensation.
I see $2.00 pps on ameritrade? not that anyone deserves more executive compensation; especially after the R/S and raise
LEXXW hit a high of $1.63 today, now at $1.00.
Ted Ohashi-Bunka Interview Pg. 6
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_8974e903d744400a8f0bd05b703a21c3.pdf
We could improve the Oral Nicotine Pouch, Zyn that Swedish Match makes. They are currently the biggest oral nicotine pouch seller in the world. Also, if Phillip Morris International acquired Swedish Match then they would be upping their competition against Altria in the US for oral nicotine. Whoever finds an edge to a better product could end up dominating the market with the pouches, not only in the US but around the world.
Our study this summer NIC-H22-1 will actually be comparing both Altria's "On" pouches and SM's "Zyn" pouches with and without DehydraTECH to entice the companies to move ahead with incorporating our tech.
https://ir.lexariabioscience.com/news-events/press-releases/detail/170/lexaria-provides-update-on-human-nicotine-study-nic-h22-1
https://www.ft.com/content/ef5aa545-f017-4dc1-8955-76b6e1a5ee8b
Ok so what product do they have LEXX can make better?
No, our tech is a process with substances that get mixed with their products to improve them. My point in linking this deal is to show that the popularity of Oral pouches is escalating and this is when better products become more important. I'm sure you didn't miss how Altria is now re-evaluating our tech as I'm sure they are always interested in making their products better. That's what smart businesses do!
The DehydraTECH IP is the product.
This means licensing - and patents to protect them - is how the business intends to make money.
Perhaps surprisingly, no one wants to license IP without proof it's going to work first.
Studies provide (or don't) said proof.
All that said, they're pursuing a product too now; so, we'll see how they fare there.
You are a dreamer Kevin
@codfather: your comment reminds me a little of a lengthy post by someone who said he used to work at Lexaria at one time. I think he said his name was Finn, perhaps Wm Finn. Anyhow, he had positive things to say about the company, something along the lines of these people are 'the real deal,' and that they really do care about the company. On the other hand, he said, he thought there needed to be more of a focus on marketing/selling their product(s). Rather than, I suppose, the incessant focus on studies as a marker of progress in themselves.
They actually make something to sell.Not just an idea
The article is about much more than kmart. If you read past the first paragraph you'll see what I mean. Also, good luck trying to dictate what any CEO wants to pay themselves.
@abundance I guess what I'd like to see is someone as CEO, not even necessarily an outsider, maybe one of the other principals, who has more of a science background. I'd also like to see their compensation somehow tied to actual results. As for the article you linked to, the example of K-Mart isn't really that good, imo. The problems with K-Mart had to do with secular changes in the retail space that would have been hard to rectify vis a vis K-Mart. Anyhow, basically after the uplisting they put out a message congratulating themselves about it, which would have been fine if it had produced positive results. Unfortunately, that has not happened so far.
Bumka is on a golf course rightnow and he doesn't give a fuck about shareholders, but he is grateful for his large salary that allowes him to live large on our dime.
IMO Bunka's positive skills and achievements far outweigh any negative ones and I believe he's the best choice we've got to lead us to a huge success. Bunka built this company with John Docherty and the rest of their team from scratch and know this company better than any newcomer ever will. Here's a great article that illustrates why switching out a CEO is usually dooming the company to a complete failure and bankruptcy. Is that what you all want?
https://hbr.org/2002/12/holes-at-the-top-why-ceo-firings-backfire
@ agent smith, codfather et al: Thanks. I feel the same way, at least it's sending a message if nothing else.
I voted against every time they have ask my opinion. The question they should be addressing is why the stock is in the toilet continuously
IMHO, if everyone who isn't Bunka or management voted "Against", it would still deliver a "vote-of-no-confidence" type of message to Bunka and management, sure!
I agree with Codfather... but imho free shares for incompetence..BUNKO should have been gone a few years ago and BOD replaced.
Pointless exercise Bunka has enough shares to carry all votes
@any shareholder: voting for officers: I just received materials asking shareholders to vote for executive officers. I will vote against C. Bunka. Does anyone have any advice about whether to vote for or against any of the others? They are:
2) John Docherty
3) William (Ted) McKechnie
4) Nicholas Baxter
5) Albert Reese
There is also a question about compensation: "Approval of Executive Officer Compensation for the 2021 Fiscal Year". I will vote against.
Jrhttps://www.colonialstock.com/Owner/proxyDocs/444.2022.ProxyCard.pdf
Any positive press and this gets squeezed to double digits real quick. Come on Bunka, say something that means something!!
I guess they hang onto them in the hope that someday they'll increase in value. If they sold them now, even if they could find a buyer, it would mean that they sold the rights to Hill Street for a pittance. Shares in Hill Street are near worthless. .025/sh.
How long can LEXX stay below Market threshold before they get removed?
@Shawking this may be a dumb question, but what does the company do with those shares?
No wonder we're on a roll, we just got 4.18 million shares of Hill Street worth a whole CDN$125,400. Wow! Whoopee!
Mr. Craig Binkley reports
HILL STREET ISSUES FINAL TRANCHE OF PAYMENT SHARES TO LEXARIA FOR DEHYDRATECH(TM) PATENT RIGHTS ACQUISITION
Hill Street Beverage Company Inc. has issued 4,188,948 common shares to Lexaria CanPharm ULC, a cannabis-related division of Lexaria Bioscience Corp., as the third and final tranche of shares to be issued in satisfaction of a deferred payment obligation for the previously announced acquisition by Hill Street of the exclusive global rights to use Lexaria's groundbreaking DehyraTech patent portfolio to produce non-pharmaceutical products containing 0.3 per cent or greater THC (tetrahydrocannabinol) and other psychoactive cannabinoids.
"The acquisition of the rights to DehyraTech has transformed our business financially, operationally and geographically, as evidenced by the company's strong growth and financial performance detailed in the update we shared last week," stated Hill Street chief executive officer Craig Binkley. "The key metrics of the business have improved substantially since this acquisition was completed 16 months ago, and we are expanding geographically on the early success of DehyraTech licensing with multiple licensees."
In accordance with the terms of the acquisition, the consideration shares were issued at a deemed price of 8.5 cents per share, being the closing price of Hill Street's common shares on the TSX Venture Exchange on Nov. 18, 2020, the date that the acquisition agreement was executed.
The consideration shares will be subject to a statutory hold period expiring on the date that is four months and one day from the issuance date.
About Hill Street Beverage Company Inc.
Hill Street Beverage Company is a progressive non-alcoholic beverage and cannabis solutions company. It is pioneering the space where craft consumer products meet bioscience by combining its deep CPG (consumer packaged good) expertise and its rights to use Lexaria Bioscience's groundbreaking DehyraTech patent portfolio for product development, licensing and B2B (business-to-business) sales of cannabis ingredients.
Hill Street Beverages brands include Vin(Zero) alcohol-free wines, and Hill Avenue Cannabis Brands include (V)ia Regal Pink and White Grape Sparklers.
We seek Safe Harbor.
Bid/offer way over the last price and not moving?????
About time management took responsibility for fucxxk up they have created
Time for another round of bonuses
More like naked shorting. The other day traded 10 times float still, fell back over the day
What’s the current short position?
Yeah - classic Lexaria: inversely-proportional news and stock price.
Followers
|
221
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
34612
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |